



SEQUENCE LISTING

RECEIVED
SEP 19 2002
TECH CENTER 1600/2900

<110> Max-Delbrueck-Centrum fuer Molekulare Medizin

<120> Tumor vaccines for mucl-positive carcinomas

<130> 0107-027

<140> Ser. No. 09/606,910

<141> 2000-06-29

<150> DE 197 58 400.4

<151> 1997-12-30

<150> PCT/DE98/03819

<151> 1998-12-30

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 7

<212> PRT

<213> human

<220>

<223> immunodominant region of MUC1

<400> 1

Pro Asp Thr Arg Pro Ala Pro

1

5

<210> 2

<211> 8

<212> PRT

<213> mouse, IgG1

<220>

<223> A76-A/C7 epitope

<400> 2

Ala Pro Asp Thr Arg Pro Ala Pro

1

5

<210> 3

<211> 6

<212> PRT

<213> mouse, IgG1

<220>

<223> MFO6 epitope

<400> 3

Asp Thr Arg Pro Ala Pro

1

5

<210> 4

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: designed
synthetical glycopeptide

<400> 4

Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser

1

5

10

15

Thr Ala Pro Pro Ala

20

<210> 5

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: designed
synthetical glycopeptide

<400> 5

His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr

1

5

10

15

Ala Pro Pro Ala

20

<210> 6

<211> 7

<212> PRT

<213> human

<220>

<221> DOMAIN

<222> (1)..(7)

<223> immunodominant motif of the epithelial mucin (
MUC1)

<400> 6

Pro Asp Thr Arg Pro Ala Pro

1

5